Long-term (≥8 years) outcome after palmaz-schatz stent implantation

Choussat, Rémi; Klersy, Catherine; Black, Alexander; Bossi, Irene; Laurent, Jean‐Pierre; Jordan, Claus; Guagliumi, Giulio; Fajadet, Jean; Marco, Jean

doi:10.1016/s0002-9149(01)01577-6

Cited by 51 publications

(39 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Long-term outcome of clinical follow-up in the present study confirmed the observation of Choussat et al, 10 who reported the rate of revascularization of stented sites was Ͻ10% beyond 1 year for up to 10 years, and late revascularization was performed predominantly to treat progressive disease at nontarget sites. Therefore, the clinical benefits of coronary stenting in terms of reduction in the rate of TL revascularization seemed to be sustained at 7 to 11 years of follow-up.…”

Section: Discussionsupporting

confidence: 90%

“…Medium-term follow-up studies at 3 to 5 years revealed a paucity of late clinical stent-related problems 4 -8 and even angiographic regression of the stented lesions. 8,9 Recently, Choussat et al 10 reported clinical stability of the stented target site at 8 to 10 years after coronary stenting. However, there is still no long-term angiographic data supporting sustained patency of the stented target site and absence of local complications specific for permanent implantation of metallic prosthesis.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Long-Term Clinical and Angiographic Follow-Up After Coronary Stent Placement in Native Coronary Arteries

et al. 2002

View full text Add to dashboard Cite

Background — Although coronary stents have been proved effective in reducing clinical cardiac events for up to 3 to 5 years, longer term clinical and angiographic outcomes have not yet been fully clarified. Methods and Results — To evaluate longer term (7 to 11 years) outcome, clinical and angiographic follow-up information was analyzed in 405 patients with successful stenting in native coronary arteries. Primary or secondary stabilization, which was defined as freedom from death, coronary artery bypass grafting, and target lesion-percutaneous coronary intervention (TL-PCI) during the 14 months after the initial procedure or after the last TL-PCI, was achieved in 373 patients (92%) overall. Only 7 patients (1.7%) underwent TL-PCI more than twice. After the initial 14-month period, freedom from TL-PCI reached a plateau at 84.9% to 80.7% over 1 to 8 years. However, quantitative angiographic analysis in 179 lesions revealed a triphasic luminal response characterized by an early restenosis phase until 6 months, an intermediate-term regression phase from 6 months to 3 years, and a late renarrowing phase beyond 4 years. Minimal luminal diameter in 131 patients with complete serial data were 2.62±0.4 mm immediately after stenting, 2.0±0.49 mm at 6 months, 2.19±0.49 mm at 3 years, and 1.85±0.56 mm beyond 4 years ( P <0.0001). Conclusions — The efficacy and safety of coronary stenting seemed to be clinically sustained at 7 to 11 years of follow-up. However, late luminal renarrowing beyond 4 years was common, which demonstrates the need for further follow-up.

show abstract

Section: Discussionsupporting

confidence: 90%

mentioning

confidence: 99%

Long-Term Clinical and Angiographic Follow-Up After Coronary Stent Placement in Native Coronary Arteries

et al. 2002

View full text Add to dashboard Cite

show abstract

“…Choussat et al [1] reported that clinical stability of the stented target site is at 8-10 years after coronary stenting. By contrast, Kimura et al [2] reported that 7-11 years of angiographic followup demonstrated late luminal renarrowing beyond 4 years, which did not necessarily require target lesion PCI.…”

Section: Clinical Course Of Isr After Bare-metal Stent (Bms) Implantamentioning

confidence: 99%

Intracoronary Imaging and Histopathology of Late Phase In-Stent Restenosis after Coronary Stent Implantation

Ito

Nakasuka

Sekimoto

et al. 2012

ISRN Vascular Medicine

View full text Add to dashboard Cite

In the field of coronary artery stenting, restenosis issue has been almost resolved after development of drug-eluting stents (DESs). In-stent restenosis (ISR) is generally considered to be a stable process, with an early peak in intimal hyperplasia followed by a quiescent period beginning 1 year after stent implantation. However, recently, extended-term problem (over 1 year) in both baremetal stents (BMSs) and DES has been reported. This phenomenon seems to be different from early ISR within one year in terms of its mechanism, prevention, and treatment. In this paper, we discuss this topic from the standpoint of intracoronary imagings and histopathology, referencing several interesting cases we experienced.

show abstract

“…Mechanistically, IL-6 contributes to CAD development by affecting metabolic, endothelial and coagulant events, and is viewed as a local and circulating marker of coronary plaque inflammation. IL-6 was implicated in the pathogenesis of ischemic cardiovascular events, including unstable angina11 and ACS,12 and its expression and secretion are regulated by IL-1 and TNF-α, which are highly induced in the atherosclerotic plaque 1314. IL-6 induces the expression of tissue factor, monocyte chemotactic protein-1, matrix-degrading enzyme and low-density lipoprotein receptors in macrophages, and stimulates the aggregation of platelets, proliferation of vascular smooth muscle cells and production of C-reactive protein and fibrinogen 1315…”

mentioning

confidence: 99%

-174G>C interleukin-6 gene polymorphism in Tunisian patients with coronary artery disease

Ghazouani

Abboud

Khalifa

et al. 2011

Annals of Saudi Medicine

View full text Add to dashboard Cite

BACKGROUND AND OBJECTIVES:A state of low-grade inflammation accompanies the pathogenesis of atherosclerotic events. Interleukin-6 (IL-6) is a pleotropic pro-inflammatory cytokine that modulates the development of acute coronary syndromes (ACSs), partly by destabilizing coronary atherosclerotic plaques. We have examined the contribution of the -174G>C IL-6 promoter variant on the risk of coronary artery disease (CAD) among Tunisians.PATIENTS AND METHODS:Study subjects included 418 CAD patients and 406 age- and sex-matched controls. IL-6 genotyping was done by PCR–restriction fragment length polymorphism.RESULTSThe frequency of the -174C allele (mutant) was lower in Tunisians than in Europeans, and the distribution of -174 G>C genotypes was similar between CAD patients and control subjects. Moreover, compared to GG genotype carriers, -174C allele carriage did not increase the CAD relative risk (odds ratio and 95% confidence interval=1.09 and 0.80-1.49), which remained nonsignificant after adjusting for traditional risk factors for CAD (age, smoking, hypertension, diabetes and obesity).CONCLUSIONThe -174G>C IL-6 promoter variant is not associated with an increased risk of CAD among Tunisians.

show abstract

Long-term (≥8 years) outcome after palmaz-schatz stent implantation

Cited by 51 publications

References 31 publications

Long-Term Clinical and Angiographic Follow-Up After Coronary Stent Placement in Native Coronary Arteries

Long-Term Clinical and Angiographic Follow-Up After Coronary Stent Placement in Native Coronary Arteries

Intracoronary Imaging and Histopathology of Late Phase In-Stent Restenosis after Coronary Stent Implantation

-174G>C interleukin-6 gene polymorphism in Tunisian patients with coronary artery disease

Contact Info

Product

Resources

About